Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 129 participants.

Also called NCT05612035

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 129 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05612035
  • EU CT 2022-501201-13-00
  • WHO UTN U1111-1279-8512
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Australia, Austria, Belgium, Colombia, France, Germany, Guatemala, Israel, Italy, Mexico, Peru, South Africa, South Korea, Spain, Switzerland, Türkiye, United Kingdom (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT05612035. Randomized; triple masking; primary purpose treatment. Start 2023-03-16 (actual); primary completion 2026-04-09 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD
Condition
Chronic Obstructive Pulmonary Disease
Intervention (Drug)
Frespaciguat
Intervention (Drug)
Placebo
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct05612035
Content hash
4fd35fdfe062b980672977aaa855570255f812f91280c0a00f4ed85dfbdf98ca